• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大鼠血管加压素V(1b)受体首个选择性激动剂的设计与合成:基于脱氨基-[半胱氨酸1]精氨酸血管加压素4位和8位的修饰

Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.

作者信息

Pena Ana, Murat Brigitte, Trueba Miguel, Ventura Maria A, Wo Nga C, Szeto Hazel H, Cheng Ling Ling, Stoev Stoytcho, Guillon Gilles, Manning Maurice

机构信息

Institut de Génomique Fonctionnelle, CNRS UMR 5203-INSERM U.661, Université Montpellier I et II, 34094 Montpellier Cedex 05, France.

出版信息

J Med Chem. 2007 Feb 22;50(4):835-47. doi: 10.1021/jm060928n.

DOI:10.1021/jm060928n
PMID:17300166
Abstract

The neurohypophyseal peptides arginine vasopressin (AVP) and oxytocin (OT) mediate a wide variety of peripheral and central physiological and behavioral effects by acting on four different G-protein coupled receptors, termed V1a (vascular), V1b (pituitary), V2 (renal), and OT (uterine). We recently reported that d[Cha4]AVP (A), d[Leu4]AVP (B), d[Orn4]AVP (C), and d[Arg4]AVP (D) have high affinity and are selective agonists for the human V1b receptor. However, peptides A-D were subsequently shown to be potent antidiuretic agonists in the rat and are, thus, not selective V1b agonists in the rat. Peptides A-D served as leads for the studies reported here. They were modified at position 8 by Lys, ornithine (Orn), diaminobutyric acid (Dab), and diaminopropionic acid (Dap) to give d[Cha4,Lys8]VP (1), d[Cha4,Orn8]VP (2), d[Cha4,Dab8]VP (3), d[Cha4,Dap8]VP (4), d[Leu4,Lys8]VP (5), d[Leu4,Orn8]VP (6), d[Leu4,Dab8]VP (7), d[Leu4,Dap8]VP (8), d[Orn4,Lys8]VP (9), d[Orn4,Orn8]VP (10), d[Arg4,Lys8]VP (11), d[Arg4,Orn8]VP (12), and d[Arg4,Dab8]VP (13). All peptides were synthesized by the Merrifield solid-phase method. Their binding and functional properties were evaluated in rat AVP V1a, V1b, and V2 receptors and on the rat OT receptor expressed either in native tissues or in stably transfected cells. They were also examined in rat vasopressor, antidiuretic, and in in vitro (no Mg++) oxytocic assays. Functional studies performed on chinese hamster ovary cells expressing the different AVP/OT receptors confirm that d[Cha4,Lys8]VP (1), d[Cha4,Dab8]VP (3), d[Leu4,Lys8]VP (5), and d[Leu4,Dap8]VP (8) are the first selective agonists for the rat V1b receptor. These selective V1b agonists are promising new tools for studies of the role of the V1b receptor in the rat.

摘要

神经垂体肽精氨酸加压素(AVP)和催产素(OT)通过作用于四种不同的G蛋白偶联受体发挥多种外周和中枢生理及行为效应,这四种受体分别称为V1a(血管)、V1b(垂体)、V2(肾脏)和OT(子宫)受体。我们最近报道,d[Cha4]AVP(A)、d[Leu4]AVP(B)、d[Orn4]AVP(C)和d[Arg4]AVP(D)对人V1b受体具有高亲和力且为选择性激动剂。然而,肽A - D随后被证明在大鼠中是强效抗利尿激动剂,因此在大鼠中并非选择性V1b激动剂。肽A - D是本研究报道的先导化合物。它们在第8位被赖氨酸、鸟氨酸(Orn)、二氨基丁酸(Dab)和二氨基丙酸(Dap)修饰,得到d[Cha4,Lys8]VP(1)、d[Cha4,Orn8]VP(2)、d[Cha4,Dab8]VP(3)、d[Cha4,Dap8]VP(4)、d[Leu4,Lys8]VP(5)、d[Leu4,Orn8]VP(6)、d[Leu4,Dab8]VP(7)、d[Leu4,Dap8]VP(8)、d[Orn4,Lys8]VP(9)、d[Orn4,Orn8]VP(10)、d[Arg4,Lys8]VP(11)、d[Arg4,Orn8]VP(12)和d[Arg4,Dab8]VP(13)。所有肽均通过Merrifield固相法合成。在大鼠AVP V1a、V1b和V2受体以及在天然组织或稳定转染细胞中表达的大鼠OT受体上评估了它们的结合和功能特性。还在大鼠升压、抗利尿以及体外(无Mg++)催产素试验中对它们进行了检测。对表达不同AVP/OT受体的中国仓鼠卵巢细胞进行的功能研究证实,d[Cha4,Lys8]VP(1)、d[Cha4,Dab8]VP(3)、d[Leu4,Lys8]VP(5)和d[Leu4,Dap8]VP(8)是大鼠V1b受体的首批选择性激动剂。这些选择性V1b激动剂是研究大鼠V1b受体作用的有前景的新工具。

相似文献

1
Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.大鼠血管加压素V(1b)受体首个选择性激动剂的设计与合成:基于脱氨基-[半胱氨酸1]精氨酸血管加压素4位和8位的修饰
J Med Chem. 2007 Feb 22;50(4):835-47. doi: 10.1021/jm060928n.
2
Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.基于对[脱氨基-半胱氨酸1]精氨酸加压素4位的修饰设计人血管加压素V1b受体的强效和选择性激动剂。
J Med Chem. 2004 Apr 22;47(9):2375-88. doi: 10.1021/jm030611c.
3
Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.[脱氨基半胱氨酸(1)]精氨酸加压素的4位类似物在人源和大鼠V(2)/V(1b)受体选择性方面表现出显著的物种差异。
J Pept Sci. 2006 Mar;12(3):190-8. doi: 10.1002/psc.710.
4
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.血管加压素和催产素V1a、V1b、V2及OT受体的肽类和非肽类激动剂与拮抗剂:研究工具及潜在治疗药物
Prog Brain Res. 2008;170:473-512. doi: 10.1016/S0079-6123(08)00437-8.
5
Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.d[亮氨酸4,赖氨酸8]加压素的药理学和生理学特性,首个针对大鼠加压素/催产素受体的V1b选择性激动剂。
Endocrinology. 2007 Sep;148(9):4136-46. doi: 10.1210/en.2006-1633. Epub 2007 May 10.
6
[1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.[1-脱氨基-4-环己基丙氨酸]精氨酸加压素:一种强效且特异性的血管加压素V1b受体激动剂。
Endocrinology. 2002 Dec;143(12):4655-64. doi: 10.1210/en.2002-220363.
7
An exploration of the effects of L- and D-tetrahydroisoquinoline-3-carboxylic acid substitutions at positions 2, 3 and 7 in cyclic and linear antagonists of vasopressin and oxytocin and at position 3 in arginine vasopressin.探索L-和D-四氢异喹啉-3-羧酸取代在血管加压素和催产素的环状和线性拮抗剂的2、3和7位以及精氨酸血管加压素的3位的作用。
J Pept Sci. 1995 Jan-Feb;1(1):66-79. doi: 10.1002/psc.310010109.
8
Synthesis and structure-activity investigation of novel vasopressin hypotensive peptide agonists.新型血管加压素降压肽激动剂的合成与构效关系研究
J Pept Sci. 1999 Nov;5(11):472-90. doi: 10.1002/(SICI)1099-1387(199911)5:11<472::AID-PSC217>3.0.CO;2-A.
9
Design and synthesis of potent, highly selective vasopressin hypotensive agonists.强效、高选择性血管加压素降压激动剂的设计与合成。
J Pept Sci. 2006 Sep;12(9):592-604. doi: 10.1002/psc.756.
10
Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.催产素和血管加压素拮抗剂中Asn5的等排取代导致高选择性和强效的催产素及V1a受体拮抗剂:用于早产潜在宫缩抑制剂设计的新方法。
J Pharmacol Exp Ther. 1996 May;277(2):999-1003.

引用本文的文献

1
Like sisters but not twins - vasopressin and oxytocin excite BNST neurons via cell type-specific expression of oxytocin receptor to reduce anxious arousal.如同姐妹而非双胞胎——血管加压素和催产素通过催产素受体的细胞类型特异性表达来兴奋终纹床核神经元,从而减少焦虑性觉醒。
bioRxiv. 2024 Sep 28:2024.09.06.611656. doi: 10.1101/2024.09.06.611656.
2
Vasopressin and Its Analogues: From Natural Hormones to Multitasking Peptides.血管升压素及其类似物:从天然激素到多功能肽。
Int J Mol Sci. 2022 Mar 12;23(6):3068. doi: 10.3390/ijms23063068.
3
Oxytocin and vasopressin: Signalling, behavioural modulation and potential therapeutic effects.
催产素和血管升压素:信号转导、行为调节及潜在的治疗效果。
Br J Pharmacol. 2022 Apr;179(8):1544-1564. doi: 10.1111/bph.15481. Epub 2021 May 21.
4
Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species.对催产素进行细微的修饰可以产生保留效力并提高跨物种选择性的配体。
Sci Signal. 2017 Dec 5;10(508):eaan3398. doi: 10.1126/scisignal.aan3398.
5
The involvement of V1b-subtype vasopressin receptors in regulation of potassium ions excretion in the rat kidneys.V1b 亚型血管升压素受体参与大鼠肾脏钾离子排泄的调节。
Dokl Biol Sci. 2014 Nov;459:338-40. doi: 10.1134/S001249661406009X. Epub 2015 Jan 6.
6
The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors.《2013/14药理学简明指南:G蛋白偶联受体》
Br J Pharmacol. 2013 Dec;170(8):1459-581. doi: 10.1111/bph.12445.
7
Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics.催生素和血管加压素激动剂和拮抗剂作为研究工具和潜在的治疗方法。
J Neuroendocrinol. 2012 Apr;24(4):609-28. doi: 10.1111/j.1365-2826.2012.02303.x.
8
Design, synthesis, and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors.设计、合成及荧光肽的药理学特性鉴定用于人 V1b 血管加压素或催产素受体的成像。
J Med Chem. 2011 Apr 28;54(8):2864-77. doi: 10.1021/jm1016208. Epub 2011 Mar 23.
9
Attenuated stress response to acute restraint and forced swimming stress in arginine vasopressin 1b receptor subtype (Avpr1b) receptor knockout mice and wild-type mice treated with a novel Avpr1b receptor antagonist.精氨酸加压素 1b 受体亚型(Avpr1b)受体敲除小鼠和经新型 Avpr1b 受体拮抗剂处理的野生型小鼠对急性束缚和强迫游泳应激的应激反应减弱。
J Neuroendocrinol. 2010 Nov;22(11):1173-80. doi: 10.1111/j.1365-2826.2010.02070.x.
10
The vasopressin Avpr1b receptor: molecular and pharmacological studies.加压素受体 Avpr1b:分子与药理学研究。
Stress. 2011 Jan;14(1):98-115. doi: 10.3109/10253890.2010.512376. Epub 2010 Sep 9.